GlassScriptPhysician profile
Paula D Moore
NPI 1952452260
$905.70
in general payments reported to CMS, 2019-2025
12 companies · $30.64 in 2025
The $30.64 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $309 · 2021: $201 · 2022: $37.28 · 2023: $15.57 · 2025: $30.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $242.27 | 2019-2020 | |
| Preventice Services, LLC | $211.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.54 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.70 | 2020-2022 | |
| Eisai INC. | $31.50 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $30.64 | 2025 | |
| Bausch Health US, LLC | $24.24 | 2020 | |
| Akcea Therapeutics, INC. | $17.35 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.57 | 2023 | Quviviq |
| G Medical Diagnostic Services, INC. | $14.91 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.35 | 2019 | |
| Irhythm Technologies, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.